A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.

To ensure the accuracy and reproducibility of immunohistochemical assays for determining HER-2/neu status of patients with breast cancer, a reliable standard for monitoring assay sensitivity is necessary. We optimally fixed and paraffin processed human ovarian and breast carcinoma cell lines SKOV-3, MDA-MB-453, BT-20, and MCF-7 in quantities sufficient to meet the needs of a laboratory for the foreseeable future. The material was tested, alongside HercepTest kit cell lines (DAKO, Carpinteria, CA), by 7 breast cancer centers in the United Kingdom and France with different immunohistochemical assays and markers. The cell lines also were analyzed by fluorescence in situ hybridization (FISH) by 2 centers using HER-2/neu kits. FISH produced 100% agreement between the 2 centers: SKOV-3 and MDA-MB-453 showed HER-2/neu amplification and BT-20 and MCF-7 did not. Immunohistochemical analysis and a common evaluation method produced 100% agreement that SKOV-3 and MCF-7 showed 3+ and zero HER-2/neu overexpression, respectively. For MDA-MB-453, there was 71% (5/7) concordance of 2+ immunohistochemical staining and 86% (6/7) concordance of zero or 1 + staining for BT-20. The cell lines provide a valuable standard for gauging HER-2/neu assay sensitivity irrespective of the antibody, antigen retrieval system, detection system, or method of evaluation used.

[1]  H. Bauchner,et al.  What have we learnt from the Alder Hey affair? , 2001, BMJ : British Medical Journal.

[2]  M. Hunter.  Alder Hey report condemns doctors, management, and coroner , 2001, BMJ : British Medical Journal.

[3]  L. Bobrow,et al.  Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. , 2001, American journal of clinical pathology.

[4]  M. Vijver,et al.  Assessment of problems in diagnostic and research immunohistochemistry associated with epitope instability in stored paraffin sections. , 2000 .

[5]  M. J. van de Vijver,et al.  Assessment of Problems in Diagnostic and Research Immunohistochemistry Associated With Epitope Instability in Stored Paraffin Sections , 2000, Applied immunohistochemistry & molecular morphology : AIMM.

[6]  I. Ellis,et al.  Recommendations for HER2 testing in the UK , 2000, Journal of clinical pathology.

[7]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Simon,et al.  Comparative methodological analysis of erbB‐2/HER‐2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use , 2000, Histopathology.

[9]  A. Vincent-Salomon,et al.  Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma , 2000, Modern Pathology.

[10]  D. Barnes,et al.  Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening , 2000, Journal of clinical pathology.

[11]  C. Compton,et al.  College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. , 2000, Archives of pathology & laboratory medicine.

[12]  B. Jasani,et al.  Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries , 2000, Journal of clinical pathology.

[13]  C. Busch,et al.  Paraffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen. , 2000, Applied immunohistochemistry & molecular morphology : AIMM.

[14]  A. Gown,et al.  HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. , 2000, American journal of clinical pathology.

[15]  D. Barnes,et al.  Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.

[16]  D. Allred,et al.  Testing for erbB-2 by immunohistochemistry in breast cancer. , 2000, American journal of clinical pathology.

[17]  D. Visscher,et al.  Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization , 2000, Modern Pathology.

[18]  Raymond R Tubbs,et al.  The Quality of Her-2/Neu Predictive Immunohistochemistry: Something FISHy? , 2000, Modern Pathology.

[19]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Swanson.  Labels, disclaimers, and rules (oh, my!). Analyte-specific reagents and practice of immunohistochemistry. , 1999, American journal of clinical pathology.

[22]  C. Taylor.  FDA issues final rule for classification and reclassification of immunochemistry reagents and kits. , 1999, American journal of clinical pathology.

[23]  J. Riera,et al.  Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer. The Quicgel method. , 1999, American journal of clinical pathology.

[24]  J. Wisecarver.  HER-2/neu testing comes of age. , 1999, American journal of clinical pathology.

[25]  J. Ingle,et al.  Increased HER2 with U.S. Food and Drug Administration-approved antibody. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Roquancourt,et al.  Variability of immunohistochemical reactivity on stored paraffin slides. , 1998, Journal of clinical pathology.

[28]  Clive R. Taylor,et al.  FDA Issues Final Rule for Classification/Reclassification of Immunochemistry Reagents and Kits , 1998 .

[29]  T. Fleming,et al.  Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial , 1998 .

[30]  S. Ruby,et al.  Quality control of proliferation marker (MIB-1) in image analysis systems utilizing cell culture-based control materials. , 1996, American journal of clinical pathology.

[31]  S. Schnitt,et al.  Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. , 1996, Journal of the National Cancer Institute.

[32]  S. Ruby,et al.  Quality control of imprint and tissue section DNA ploidy analysis in image analysis systems utilizing cell culture-based control materials. , 1995, American journal of clinical pathology.

[33]  M. Kraus,et al.  Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms. , 1987, The EMBO journal.

[34]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[35]  F. Rosato,et al.  Diseases of the Breast , 1972 .